The pertussis vaccine is a preparation designed to protect against whooping cough, a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It works by exposing the immune system to either killed whole bacteria or purified bacterial proteins so the body can recognize and fight the real pathogen before it causes severe illness. Two fundamentally different versions exist today, whole-cell and acellular, and the distinction between them matters more than most people realize. The acellular version used in most high-income countries is safer and better tolerated, but it trains the immune system in a way that fades faster and may not fully block transmission.
What the Bacterium Does and Why a Vaccine Helps
Bordetella pertussis targets the airways specifically. The bacterium produces surface proteins, particularly filamentous hemagglutinin and pertussis toxin, that act together as adhesins, allowing it to latch onto the cilia lining human respiratory passages.1The Journal of Infectious Diseases. Characterization of Two Adhesins of Bordetella pertussis for Human Ciliated Respiratory-Epithelial Cells Once anchored, it releases toxins that paralyze the cilia, trigger intense inflammation, and produce the characteristic uncontrollable coughing fits that give the disease its name. In infants, these fits can cause apnea, brain damage, and death. The vaccine’s job is to prime the immune system to recognize those bacterial components, especially pertussis toxin and the adhesion proteins, so it can neutralize the bacterium before it establishes a foothold.
Whole-Cell Versus Acellular Vaccines
The original pertussis vaccines, developed in the mid-twentieth century, were whole-cell formulations. They contained entire killed B. pertussis bacteria, which meant the immune system encountered hundreds of bacterial components at once. These vaccines were effective; large-scale use markedly reduced whooping cough in young children, with most formulations providing protective immunity lasting roughly two to five years.2PubMed. Bordetella pertussis whole cell vaccines–efficacy and toxicity The trade-off was reactogenicity. Local reactions and mild systemic symptoms like fever were common, and the vaccines occasionally caused convulsions, a shock-like state, and, rarely, serious neurological reactions.
Acellular pertussis vaccines were developed to solve that safety problem. Instead of injecting killed whole bacteria, they use a handful of purified bacterial proteins, typically some combination of pertussis toxoid (a detoxified version of pertussis toxin), filamentous hemagglutinin, pertactin, and fimbriae. Formulations vary: some contain as few as two components, others contain five.3PubMed. A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine These acellular vaccines produce far fewer side effects, which is why they replaced whole-cell formulations in the United States, Europe, Australia, and most other wealthy nations starting in the 1990s. In many lower-income countries, whole-cell vaccines are still used, both because they are cheaper to produce and because, immunologically, they may offer some advantages.
How the Two Types Train the Immune System Differently
This is where the story gets more interesting than a simple “old versus new” narrative. Natural infection with B. pertussis and whole-cell vaccination both push the immune system toward a response dominated by Th1 and Th17 cells. Acellular vaccines, by contrast, steer toward a Th2-dominated response.4PubMed Central. Pertussis vaccines and protective immunity In practical terms, the Th1/Th17 pathway is better at clearing bacteria from the respiratory tract and preventing colonization, while the Th2 pathway is effective at generating antibodies that prevent severe disease but less effective at stopping the bacteria from living in your nose and throat.
Research in mice has confirmed this distinction further. One study found that while an acellular vaccine did induce some Th17 and Th2 cells against B. pertussis, it failed to generate Th1 cells. Experiments in mice lacking specific immune signaling molecules showed that the Th2 pathway (driven by IL-4) was actually dispensable for protection, whereas the Th1/Th17 pathways (driven by IL-1 and IL-17A) were absolutely required.5PLoS Pathogens. Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine This helps explain why acellular vaccines keep you from getting seriously ill but may not stop you from carrying and spreading the bacterium.
The immune polarization set by your first pertussis vaccination appears to persist long term. A study comparing people who received whole-cell vaccine in infancy with those who received acellular vaccine found that even after repeated acellular boosters, the original Th1/Th17 polarization from whole-cell priming persisted. Conversely, those originally primed with acellular vaccine maintained their Th2-skewed response.6Journal of Clinical Investigation. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters Your immune system’s first encounter with pertussis antigens, in other words, sets the template that later boosters build on rather than replace.
Protection Against Disease Versus Protection Against Transmission
A landmark study in baboons made the transmission gap vivid. Animals vaccinated with the acellular vaccine were protected from severe pertussis symptoms, but they still became colonized by the bacterium after exposure. They did not clear the infection any faster than completely unvaccinated animals, and they readily transmitted B. pertussis to unvaccinated cage-mates. Whole-cell vaccination, by contrast, prevented both disease and transmission.7PubMed Central. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model A separate study confirmed the pattern: whole-cell vaccination controlled bacterial shedding and transmission, while acellular vaccination controlled disease severity but not shedding.8The Journal of Infectious Diseases. Different Effects of Whole-Cell and Acellular Vaccines on Bordetella Transmission
This distinction has real public health consequences. In a population vaccinated predominantly with acellular vaccine, people can silently carry and spread B. pertussis while feeling only mildly ill or not ill at all. Those silent carriers pose a risk to the most vulnerable: infants too young to have completed their vaccine series.
The Childhood Schedule and Waning Immunity
In countries using acellular vaccines, children typically receive a primary series of three doses in the first year of life, followed by boosters at around 15 to 18 months and again at 4 to 6 years. The protection from this series is genuine but starts declining sooner than many parents expect. After three doses, effectiveness against all reported pertussis was about 84% between six and eleven months of age, but it dropped to roughly 71% between ages two and three and to about 59% between ages three and four.9Pediatrics. Duration of Protection After First Dose of Acellular Pertussis Vaccine in Infants
The waning continues after booster doses. Evidence suggests acellular vaccine effectiveness begins to drop as early as two to three years after the last booster.10PubMed Central. What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines While other factors like better diagnosis and surveillance contribute to rising case counts, waning immunity from acellular vaccines appears to be the primary driver of pertussis resurgence in highly vaccinated populations.
Adolescent and Adult Boosters
The Tdap vaccine (tetanus, diphtheria, and acellular pertussis) is recommended for adolescents and adults. It is a lower-dose formulation compared to the DTaP given to children. A study tracking antibody levels for a decade after a Tdap booster in adults found that pertussis antibodies generally stayed above pre-vaccination levels throughout, but showed substantial waning over time.11PubMed. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA Whether repeat Tdap boosters every few years make sense for general adult populations remains an active discussion.
There is some encouraging news on longer-lasting booster formulations. A study examining pertussis immunity five years after booster vaccination with recombinant pertussis vaccines found evidence that genetically detoxified pertussis toxin-containing vaccines may offer longer-lasting protection in adolescents, supporting their use in booster programs aimed at maintaining population immunity.12JAMA Network Open. Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines
Vaccinating During Pregnancy
Because newborns are too young to be vaccinated and face the highest risk of severe disease and death from whooping cough, many countries now recommend that pregnant individuals receive a Tdap dose during the third trimester. The idea is that the mother generates high levels of pertussis antibodies, which cross the placenta and give the baby passive protection during the first vulnerable months of life.
The strategy works. At delivery, infants born to mothers who received Tdap during pregnancy had dramatically higher concentrations of antibodies against pertussis toxin, pertactin, and filamentous hemagglutinin compared to infants born to unvaccinated mothers.13PubMed Central. Effect of maternal Tdap on infant antibody response to a primary vaccination series with whole cell pertussis vaccine in São Paulo, Brazil Another study found a high correlation between antibody levels in mothers and newborns, with levels in newborns often exceeding those in the mothers themselves, suggesting the transferred antibodies should be sufficient to provide protection during the first months before the infant’s own vaccinations begin.14PubMed. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn
Cost-effectiveness analyses support maternal vaccination as well. In a modeling study across Brazilian states, maternal acellular pertussis immunization was cost-effective at roughly $2,000 to $3,100 per disability-adjusted life year averted depending on the region.15PubMed Central. Modeling the cost-effectiveness of maternal acellular pertussis immunization (aP) in different socioeconomic settings A comparative analysis in Spain estimated that vaccinating pregnant women was more efficient at preventing infant hospitalizations than the “cocooning” strategy of vaccinating all close contacts: about 1,331 pregnant women would need to be vaccinated to prevent one infant hospitalization, compared to 4,752 parents under cocooning.16PubMed. Cost-benefit of the introduction of new strategies for vaccination against pertussis in Spain: cocooning and pregnant vaccination strategies
Safety of Modern Pertussis Vaccines
The switch from whole-cell to acellular vaccines in the 1990s was driven by safety concerns, and the acellular versions have held up well under scrutiny. The most common reactions after DTaP in children are redness at the injection site (reported in about a quarter of cases), fever (about a fifth), and injection site swelling (about 15%).17PubMed Central. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines A safety study comparing DTaP-containing vaccines against historical rates of eight pre-specified serious adverse events, including meningitis, seizures, Guillain-Barré syndrome, and anaphylaxis, found no statistically significant increased risk for any of them.18PubMed. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine
In older adults, Tdap has a similarly reassuring profile. A review of adverse event reports in adults 65 and older over an eight-year period found that the vast majority of reports described non-serious events like injection site redness and pain. Only 6% of reports were classified as serious, and among seven deaths reported during the surveillance period, none were attributed to the vaccine.19PubMed. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years Co-administration of pertussis-containing vaccines with other routine childhood vaccines (like hepatitis B, polio, and Hib vaccines) has also been well studied and does not appear to cause meaningful interference with immune responses to either vaccine.20PubMed. Infant vaccine co-administration: review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines
What Antibodies Actually Correlate With Protection
One persistent challenge in pertussis vaccinology is that there is no single, universally agreed-upon “level of antibody that means you’re protected.” Still, household exposure studies have identified some useful markers. Research found that antibodies against pertactin, fimbriae, and pertussis toxin in pre-exposure blood samples correlated with clinical protection against whooping cough, and that these could serve as surrogate markers for evaluating both acellular and whole-cell vaccines.21PubMed. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
A more granular analysis found that anti-pertactin antibodies were the strongest individual predictor. People with low pertactin antibody levels had a two-thirds chance of getting infected after household exposure regardless of their other antibody levels. Those with adequate pertactin antibodies combined with high pertussis toxin antibodies were fully protected in the study sample. Interestingly, antibodies against filamentous hemagglutinin did not add additional protection once the other antibodies were accounted for.22PubMed. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses This finding matters for understanding why certain strains that have lost pertactin expression are concerning.
The Bacterium Is Evolving Around the Vaccine
Perhaps the most unsettling development in pertussis control is the rapid spread of bacterial strains that no longer produce pertactin, one of the key antigens in acellular vaccines and, as noted above, a protein whose corresponding antibodies are particularly important for protection. In the United States, most circulating B. pertussis strains have independently acquired mutations that disable pertactin production, which is strong evidence that the acellular vaccine itself is exerting selective pressure on the pathogen.23PubMed Central. Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis
Laboratory work has confirmed the mechanism. In mice immunized with an acellular vaccine, a pertactin-negative strain colonized the respiratory tract more effectively than a pertactin-positive strain, outcompeting it within three days of co-infection.24PubMed. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model In unvaccinated animals, the two strains were evenly matched. The vaccine, in effect, creates an environment where bacteria that have dropped pertactin have a survival advantage. Current acellular vaccines still provide meaningful protection against pertactin-negative strains through antibodies targeting the other included antigens, but the erosion of one protective component is a trend worth watching closely.
Global Disparities in Pertussis Burden
Worldwide, pertussis vaccine programs have transformed the disease landscape, but unevenly. Africa’s reported incidence plummeted from over 1,100 cases per million in 1980 to fewer than 5 per million by 2023, largely through expanding childhood immunization with affordable whole-cell vaccines. The Eastern Mediterranean region saw a similar decline. Europe’s incidence also fell dramatically but has shown cyclical fluctuations, with outbreaks peaking roughly every three to five years.25PubMed Central. Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance Those European cycles are a hallmark of the waning-immunity dynamic with acellular vaccines: each cohort of children gradually loses protection, and when enough susceptible people accumulate, an outbreak ignites.
The situation is paradoxical in some ways. Countries with the highest vaccination rates, which tend to use acellular vaccines exclusively, are seeing periodic resurgences. Countries still using whole-cell vaccines report lower incidence overall, though poorer surveillance infrastructure makes direct comparison tricky. The gap highlights the tension at the heart of pertussis control: the safest and most tolerable vaccine is not the one that creates the most durable or transmission-blocking immunity.
Next-Generation Vaccines in Development
Researchers are trying to close the gaps left by current acellular vaccines, and the most advanced candidate takes a fundamentally different approach. BPZE1 is a live attenuated pertussis vaccine delivered as a nasal spray rather than an injection. It was created by genetically detoxifying pertussis toxin and removing two other harmful components, dermonecrotic toxin and tracheal cytotoxin.26The Lancet Infectious Diseases. Safety and efficacy of BPZE1, a live attenuated pertussis vaccine, in a controlled human infection model Because it is a live but weakened bacterium delivered to the nose, it colonizes the respiratory tract briefly and provokes the kind of mucosal immune response that acellular vaccines largely miss.
Early clinical trials have confirmed that BPZE1 safely colonizes the nasal passages and produces an immune response, supporting further development either as a priming vaccine for newborns or a booster for adolescents and adults.27The Lancet Infectious Diseases. Safety, colonisation, and immunogenicity of a live attenuated pertussis vaccine If an intranasal vaccine can trigger Th1/Th17 responses and mucosal immunity in the airways where B. pertussis actually lives, it could potentially reduce not just disease but colonization and transmission, the major gap with current injected acellular vaccines.
The 1970s Vaccine Scare and Its Lasting Influence
The pertussis vaccine has the distinction of being at the center of one of the earliest major vaccine controversies. In the 1970s and 1980s, public backlash against the whole-cell pertussis vaccine erupted in Great Britain over concerns about serious neurological side effects. Vaccination rates plummeted, and whooping cough epidemics followed.28ScienceDirect / Vaccine. The pertussis vaccine controversy in Great Britain, 1974-1986 The controversy spread internationally, following a pattern later echoed by the MMR-autism scare: initial alarm in the UK, media amplification, declining uptake, and then outbreaks that ultimately demonstrated how essential the vaccine had been.
The British experience is worth remembering not as ancient history but as the direct ancestor of today’s vaccine landscape. The development of acellular pertussis vaccines was accelerated specifically in response to the public’s fear of whole-cell formulations. The trade-off the world accepted, a milder vaccine with shorter-lasting and less robust immunity, was not made by scientists in isolation. It was shaped by a society that demanded something gentler, and the epidemiological consequences of that choice are still playing out decades later.